STARD7 Antibody

What are the primary applications for STARD7 antibodies in research?

STARD7 antibodies are primarily used in Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and ELISA applications. Western blotting is particularly well-validated across multiple antibodies with recommended dilutions typically ranging from 1:1000-1:8000 . Immunohistochemistry applications generally require more concentrated antibody solutions (1:20-1:200) . For detecting endogenous STARD7, positive controls include HeLa cells, HepG2 cells, K-562 cells, mouse testis tissue, and Jurkat cells . The choice of application should be guided by the specific research question, with Western blotting being optimal for quantitative analysis and IHC/IF for localization studies.

What is the molecular weight of STARD7 protein that should be detected by antibodies?

STARD7 exists in two forms: a full-length precursor (StarD7-I) of approximately 43.1 kDa containing a mitochondrial targeting sequence, and a processed mature form of approximately 33-35 kDa (StarD7-II) . In most Western blot applications, antibodies typically detect a band at 34-35 kDa, corresponding to the mature form . The calculated molecular weight based on amino acid sequence is 35 kDa (295 amino acids), while the observed molecular weight in experimental conditions is approximately 34 kDa . Researchers should be aware that antibody datasheets may report slightly different observed molecular weights depending on the cell types and experimental conditions used during validation .

How should STARD7 antibodies be stored to maintain optimal reactivity?

For long-term storage, STARD7 antibodies should be kept at -20°C, where they typically remain stable for at least one year after shipment . Many commercially available antibodies are supplied in a storage buffer containing PBS with glycerol (typically 50%) and a preservative such as sodium azide (0.02%) or thimerosal (0.01%), maintaining a neutral pH (7.0-7.4) . For short-term storage (less than one month), antibodies can be kept at 4°C. It's important to avoid repeated freeze-thaw cycles, though aliquoting is often unnecessary for -20°C storage with the glycerol-containing formulations . Before use, briefly centrifuge the antibody vial to collect the solution at the bottom of the tube .

How can I validate STARD7 knockdown experiments when studying mitochondrial function?

When conducting STARD7 knockdown studies to investigate mitochondrial function, a multi-parameter validation approach is essential:

• Protein verification: Confirm STARD7 reduction by Western blot analysis using validated antibodies. Look for a significant decrease in the 34-35 kDa band .

• Mitochondrial morphology assessment: Use electron microscopy to examine mitochondrial ultrastructure, looking for disrupted mitochondrial networks, fragmented mitochondria, and altered cristae morphology as observed in previous studies .

• Mitochondrial function parameters: Measure:

  • Oxygen consumption rates

  • ATP production levels (significantly reduced in StarD7 KO cells)

  • Expression of respiratory chain components, particularly Complex I and IV subunits

• Control markers: Assess outer mitochondrial membrane (OMM) proteins like TOMM20, which should remain unchanged despite STARD7 knockdown, indicating that the total mitochondrial mass is maintained .

• Mitochondrial network analysis: Perform quantitative analysis of mitochondrial network fragmentation using fluorescent markers and confocal microscopy .

• Recovery experiments: Include rescue experiments by reintroducing StarD7-I (containing mitochondrial targeting sequence) and StarD7-II (cytosolic form) to determine which form restores mitochondrial function .

What are the optimal experimental conditions for detecting STARD7 localization in cellular compartments?

Detecting STARD7's dual localization in both mitochondria and cytosol requires careful experimental design:

• Subcellular fractionation protocol:

  • Use Percoll/Nycodenz discontinuous density gradient for mitochondrial isolation

  • Verify fraction purity with compartment-specific markers: ATP5A (mitochondria), actin (cytosol), GM130 (Golgi), PMP70 (peroxisome), and EEA1 (endosome)

• Immunofluorescence optimization:

  • PFA fixation (typically 4%) followed by Triton X-100 permeabilization

  • Co-staining with mitochondrial markers (TOMM20 for OMM, Complex I for IMM)

  • Use high-resolution confocal or super-resolution microscopy for precise localization

• Differential detection of StarD7 isoforms:

  • StarD7-I localizes primarily to mitochondria at low cellular density but redistributes to cytoplasm at high density

  • StarD7-II remains cytoplasmic regardless of cellular density

  • Use antibodies recognizing both forms or specific regions for differential detection

• Controls for mitochondrial import experiments:

  • Include carbonylcyanide-m-chlorophenylhydrazone (CCCP) treatment (50 μM, 30 min) to disrupt mitochondrial membrane potential and inhibit protein import

  • Perform pulse-chase experiments with [35S]methionine/cysteine labeling to track protein processing and localization over time

What positive and negative controls should be included when testing STARD7 antibodies?

To ensure robust and reliable results with STARD7 antibodies, include these controls:

Positive controls:

• Cell lines with validated STARD7 expression: HeLa, HepG2, K-562, Jurkat

• Tissue samples: mouse testis tissue, human colon cancer tissue

• Recombinant STARD7 protein (for antibody calibration)

Negative controls:

• STARD7 knockout cells generated using CRISPR/Cas9

• siRNA-mediated STARD7 knockdown samples

• Secondary antibody-only controls for background assessment

• Isotype controls (rabbit IgG) to identify non-specific binding

Specificity controls:

• Pre-absorption with immunizing peptide to confirm target specificity

• Detection of both StarD7-I and StarD7-II forms depending on cell type and culture conditions

• Cross-validation with multiple antibodies targeting different epitopes of STARD7

How can STARD7 antibodies be used to investigate phospholipid transport to mitochondria?

Investigating STARD7's role in phosphatidylcholine (PC) transport to mitochondria requires sophisticated experimental approaches:

• Mitochondrial phospholipid analysis:

  • Isolate highly purified mitochondria using Percoll/Nycodenz gradient centrifugation

  • Extract phospholipids and analyze by LC-MS/MS to quantify PC content in wild-type versus STARD7-deficient cells

  • Compare phospholipid profiles between cells expressing StarD7-I (mitochondrial targeting) versus StarD7-II (cytosolic)

• Phospholipid transfer assays:

  • Reconstitute phospholipid transfer activity using purified recombinant StarD7 protein

  • Establish donor vesicles containing fluorescently labeled PC (e.g., BODIPY-FL-C5-HPC)

  • Monitor fluorescence intensity changes as an indicator of lipid transfer

  • Quantify transfer rates at different protein concentrations (concentration-dependent manner)

• In situ proximity analysis:

  • Perform immunofluorescence co-localization studies of STARD7 with ER markers (origin of PC synthesis) and mitochondrial markers

  • Use proximity ligation assays to detect STARD7 at membrane contact sites between ER and mitochondria

  • Employ live-cell imaging with fluorescently tagged STARD7 to track its movement between membranes

• Co-immunoprecipitation experiments:

  • Use STARD7 antibodies to pull down protein complexes

  • Analyze associated proteins involved in phospholipid transport and membrane contact sites

  • Include appropriate controls (IgG precipitation, STARD7-deficient cells)

What is the significance of STARD7 in mitochondrial respiratory complex assembly, and how can antibodies help investigate this?

STARD7 deficiency impacts mitochondrial respiratory function and complex assembly, which can be investigated using antibodies through:

• Respiratory complex assembly analysis:

  • Use Blue Native-PAGE (BN-PAGE) with mitochondrial extracts from wild-type and STARD7-deficient cells

  • Probe with antibodies against respiratory complex components

  • Quantify assembly of respiratory chain supercomplexes

  • Focus particularly on ATP synthase dimers, which are significantly reduced in STARD7-deficient cells

• Cristae morphology correlation:

  • Combine electron microscopy analysis of cristae morphology with immunogold labeling of STARD7

  • Quantify correlations between STARD7 levels and cristae structural parameters

  • Perform rescue experiments with wild-type STARD7 versus mutant forms lacking the START domain

• Mitochondrial translation assessment:

  • Analyze levels of mitochondrial DNA-encoded respiratory complex subunits (MTCO1, MTCO2, MTCO3)

  • Compare protein levels (by Western blot) with mRNA levels (by RT-qPCR) to identify post-transcriptional effects

  • STARD7 deficiency does not affect mtDNA transcription but may impact translation or protein stability

• Functional interaction studies:

  • Investigate relationships between STARD7 and other proteins involved in cristae organization

  • Test interactions with MICOS complex, prohibitins, and OPA1 using co-immunoprecipitation

  • Determine whether phospholipid composition changes mediated by STARD7 affect the stability of these protein complexes

How do STARD7 antibodies help resolve the functional differences between StarD7-I and StarD7-II isoforms?

Differentiating the functions of StarD7-I (mitochondrial) and StarD7-II (cytosolic) isoforms requires strategic use of antibodies:

• Isoform-specific detection strategies:

  • Select antibodies recognizing epitopes within the N-terminal mitochondrial targeting sequence (unique to StarD7-I) versus the START domain (present in both isoforms)

  • Validate antibody specificity using cells expressing only one isoform

  • Use size discrimination on Western blots (43.1 kDa precursor vs. 34.7 kDa mature form)

• Proteolytic processing analysis:

  • Track StarD7-I processing by pulse-chase experiments with immunoprecipitation

  • Investigate PARL-mediated cleavage of StarD7 at the inner mitochondrial membrane

  • Examine how negatively charged amino acids (residues 86-102) promote release of processed StarD7 from mitochondria

• Functional complementation experiments:

  • Use knockout cells reconstituted with either StarD7-I or StarD7-II

  • Compare rescue efficiency for:

    • Mitochondrial PC content

    • ATP production (better restored by StarD7-I than StarD7-II)

    • Cristae morphology

    • ATP synthase dimerization

• Dynamic distribution studies:

  • Analyze how cellular conditions affect localization of each isoform

  • Examine cell density effects on StarD7-I distribution between mitochondria and cytosol

  • Investigate stress conditions that might alter isoform distribution or expression

How can STARD7 antibodies be used to investigate endoplasmic reticulum stress responses?

STARD7 deficiency induces ER stress, which can be thoroughly investigated using antibodies:

• ER stress marker panel analysis:

  • Western blot for key ER stress proteins in STARD7-deficient versus control cells:

    • IRE1α (increased with STARD7 knockdown)

    • Calnexin (increased)

    • Grp78/BiP (increased)

    • PERK (increased)

    • Phosphorylated eIF2α (increased)

• Morphological assessment:

  • Immunofluorescence co-staining of STARD7 with ER markers

  • Electron microscopy to detect morphological alterations in ER structure

  • Quantitative analysis of ER-mitochondria contact sites

• Interconnected stress response pathways:

  • Examine relationship between STARD7 deficiency and:

    • ROS generation (increased)

    • p53 expression (downregulated through degradation)

    • Antioxidant enzyme expression (HO-1 and catalase - increased)

  • Determine causality between ER stress and oxidative stress using specific inhibitors

• Cell viability correlation:

  • Assess correlation between STARD7 levels, ER stress markers, and cell viability

  • Challenge with H2O2 to examine vulnerability to oxidative stress

  • Test whether ER stress inhibitors rescue viability in STARD7-deficient cells

What experimental approaches can reveal STARD7's role in intestinal epithelial barrier function?

STARD7 maintains intestinal epithelial barrier integrity, which can be investigated through:

• Barrier integrity assessment:

  • Analyze expression of tight junction proteins in wild-type versus STARD7-deficient models:

    • Claudin-1, -3, and -4 (decreased in Stard7+/- mice)

    • Claudin-2 (increased in Stard7+/- mice)

  • Quantify epithelial permeability using FITC-dextran flux assays in vivo

• Epithelial cell model systems:

  • Use lentiviral STARD7 knockdown in colonic epithelial cells (CaCo-2BBe)

  • Perform wound healing assays to assess barrier repair capacity

  • Generate 2D epithelial cell monolayers for permeability studies

• Mitochondrial-epithelial barrier connection:

  • Co-stain for STARD7, mitochondrial markers, and junction proteins

  • Assess correlation between mitochondrial morphology alterations and barrier dysfunction

  • Measure cellular energetics (ATP levels) in relation to barrier maintenance

• Inflammatory bowel disease relevance:

  • Analyze STARD7 expression in inflamed versus healthy intestinal epithelium

  • Compare STARD7-expressing epithelial cell clusters between healthy individuals and ulcerative colitis patients

  • Assess whether STARD7 supplementation can restore barrier function in disease models

How do different experimental models affect STARD7 expression patterns, and how can this be accurately measured?

STARD7 expression varies across experimental conditions and disease states, requiring careful methodological approaches:

• Expression analysis across physiological states:

  Condition	Tissue/Cell Type	Fold Change	Regulation
  Fasted mice	Small intestine	1.4	Upregulated
  Hyperinsulinemic clamp	Skeletal muscle	3.31	Upregulated
  Lengthening vs. shortening contraction	Leg muscle biopsies	2	Downregulated
  Singing vs. non-singing behavior	Forebrain vocal nuclei	Detected	Upregulated

• Normalization strategies:

  • Select appropriate housekeeping genes based on experimental context

  • Use multiple reference genes for RT-qPCR normalization

  • For protein quantification, employ total protein normalization methods alongside traditional loading controls

  • Include positive control samples with known STARD7 expression levels

• Transcript versus protein correlation:

  • Perform parallel mRNA (RT-qPCR) and protein (Western blot) quantification

  • Assess whether post-transcriptional regulation occurs in specific conditions

  • Consider microRNA regulation (e.g., Has-miR-377 targets STARD7)

• Tissue-specific expression patterns:

  • Highest expression found in trophoblast-derived cells, hepatocellular carcinoma cells, and colorectal adenocarcinoma cells

  • Lower expression in cervix adenocarcinoma, breast adenocarcinoma, lung adenocarcinoma, melanoma, and leukemia cells

  • Validate antibody specificity in each tissue type before quantitative comparisons

What are the most common technical issues when using STARD7 antibodies, and how can they be resolved?

Researchers frequently encounter these challenges when working with STARD7 antibodies:

• Non-specific bands in Western blots:

  • Solution: Optimize blocking conditions (try 5% BSA instead of milk for phospho-specific detection)

  • Increase antibody dilution (1:5000-1:8000 for WB applications)

  • Validate with STARD7 knockout/knockdown controls

  • Consider alternative antibodies targeting different epitopes

• Weak or no signal detection:

  • Solution: Verify antibody storage conditions (-20°C long-term)

  • Test positive control samples known to express STARD7 (HeLa, HepG2, Jurkat)

  • Optimize antigen retrieval for IHC (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Decrease antibody dilution for difficult samples (1:20-1:200 for IHC)

• Discrepancies between observed molecular weights:

  • Solution: Understand the two forms of STARD7 (43.1 kDa precursor and 34.7 kDa mature form)

  • Use gradient gels (4-20%) for better resolution of closely sized proteins

  • Include purified recombinant STARD7 as size reference

  • Consider post-translational modifications that may alter migration patterns

• Poor immunofluorescence localization:

  • Solution: Optimize fixation and permeabilization protocols

  • Test different antibody concentrations (typically 2-4 μg/ml for IF)

  • Include co-staining with organelle markers to confirm localization

  • Be aware that STARD7 localization changes with cell density

How can researchers optimize protein extraction protocols specifically for STARD7 detection?

Efficient STARD7 extraction and detection requires optimization of several parameters:

• Subcellular fractionation approach:

  • For total STARD7: Use RIPA buffer with protease inhibitors

  • For mitochondrial STARD7: Employ Percoll/Nycodenz density gradient separation

  • For cytosolic STARD7: Use digitonin-based selective permeabilization

  • Verify fraction purity with compartment-specific markers

• Buffer composition optimization:

  • Include phosphatase inhibitors if studying phosphorylated forms

  • Add 1% Nonidet P-40 for enhanced solubilization

  • Consider 20 mM Tris-HCl (pH 8.0) with 0.5 M NaCl for immunoprecipitation applications

  • For mitochondrial proteins, add detergents that preserve native state (digitonin 1-2%)

• Sample preparation considerations:

  • Process samples immediately or flash-freeze in liquid nitrogen

  • Avoid repeated freeze-thaw cycles that may degrade STARD7

  • For mitochondrial preparations, maintain samples at 4°C throughout isolation

  • Consider cross-linking if studying STARD7 protein complexes

• Recombinant protein purification strategies:

  • For bacterial expression, include glycine linkers to improve column binding efficiency

  • Use isopropyl-β-D-thiogalactopyranoside (0.1 mM) for induced expression

  • Purify with Ni-Sepharose columns using imidazole elution (500 mM)

  • Validate purified protein activity through phospholipid transfer assays

How can researchers design experiments to differentiate between direct STARD7 effects and secondary consequences of disrupted lipid transport?

Distinguishing primary from secondary effects requires carefully designed experimental approaches:

• Temporal analysis strategy:

  • Perform time-course experiments after STARD7 knockdown/knockout

  • Identify earliest detectable changes (likely primary effects)

  • Use inducible knockdown systems to track sequential changes

  • Compare acute versus chronic STARD7 depletion effects

• Rescue experiment design:

  • Reintroduce wild-type STARD7 versus function-specific mutants:

    • StarD7-I (mitochondrial) versus StarD7-II (cytosolic)

    • START domain mutants that cannot bind phospholipids

    • Mitochondrial targeting sequence mutants

  • Evaluate which phenotypes are rescued by each construct

• Direct phospholipid supplementation:

  • Provide exogenous phosphatidylcholine to STARD7-deficient cells

  • Determine which phenotypes are rescued by lipid supplementation alone

  • Use cell-permeable PC analogs for direct delivery to mitochondria

  • Compare liposome-based versus carrier-mediated delivery methods

• Parallel pathway manipulation:

  • Target other PC transport proteins (StarD2/PCTP, StarD10) alongside STARD7

  • Compare phenotypic profiles between different transport protein deficiencies

  • Identify common versus unique effects to differentiate transport-related from protein-specific functions

  • Use metabolic labeling to track phospholipid movement through alternative pathways